Biosyent Inc. (CVE:RX) – Investment analysts at Cormark upped their FY2017 earnings per share (EPS) estimates for shares of Biosyent in a report issued on Thursday. Cormark analyst D. Novak now expects that the company will earn $0.35 per share for the year, up from their previous forecast of $0.32.

Biosyent (CVE:RX) last issued its quarterly earnings data on Thursday, May 25th. The company reported $0.06 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.08 by $0.02. The company had revenue of $3.82 million for the quarter, compared to the consensus estimate of $4.80 million. Biosyent had a net margin of 23.59% and a return on equity of 21.00%.

ILLEGAL ACTIVITY NOTICE: “Cormark Brokers Lift Earnings Estimates for Biosyent Inc. (RX)” was first reported by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/08/18/cormark-brokers-lift-earnings-estimates-for-biosyent-inc-rx.html.

Biosyent Company Profile

BioSyent Inc is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc, acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women’s Health Unit, which commercializes pharmaceutical products focused on improving family and women’s health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business.

Receive News & Ratings for Biosyent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosyent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.